Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Persistent/Chronic Primary ITP (Phase 2)
CTR20230147Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of mezagitamab in immune thrombocytopenia (ITP), sponsored by Takeda. Started Feb 2023; status: completed.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20230147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230147.